Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.34 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.34 |
| ▸ | ESR1 | P03372 | 1/20 | 0.31 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.31 |
| ▸ | SLC5A1 | P13866 | 1/20 | 0.31 |
| ▸ | SLC5A2 | P31639 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | ATM | Q13315 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL32667872 | 0.88 | GABRA1 (0.40) | ALDH1A1GABRA1GABRB2MEN1KMT2A | |
| SCHEMBL5597285 | 0.82 | ALDH1A1 (0.45) | ALDH1A1SLC5A1SLC5A2 | |
| SCHEMBL25084420 | 0.79 | GABRA1 (0.43) | ALDH1A1GABRA1GABRB2ESR1ESR2 | |
| SCHEMBL8792042 | 0.77 | GABRA1 (0.46) | ALDH1A1GABRA1GABRB2MEN1KMT2A | |
| SCHEMBL6580294 | 0.77 | ALDH1A1 (0.36) | ALDH1A1MEN1HSP90AA1KMT2AATM | |
| SCHEMBL11698533 | 0.76 | CYP3A4 (0.41) | ALDH1A1 | |
| SCHEMBL11871796 | 0.75 | IDO1 (0.52) | ALDH1A1KMT2A | |
| SCHEMBL24298226 | 0.75 | TSHR (0.52) | ALDH1A1 | |
| SCHEMBL6351804 | 0.74 | GABRA1 (0.41) | ALDH1A1GABRA1GABRB2ESR1ESR2 | |
| SCHEMBL21427674 | 0.73 | MEN1 (0.43) | ALDH1A1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11077090-B2 | Compounds and compositions and uses thereof | SUNOVION PHARMACEUTICALS INC. (MA) | 2021-08-03 | — | — | US | disclosed |
| EP-3490607-A1 | COMPOUNDS AND COMPOSITIONS AND USES THEREOF | Sunovion Pharmaceuticals Inc. (US) | 2019-06-05 | — | — | EP | disclosed |
| US-20180028492-A1 | COMPOUNDS AND COMPOSITIONS AND USES THEREOF | PGI DRUG DISCOVERY LLC | 2018-02-01 | — | — | US | disclosed |
| US-20180028492-A1 | COMPOUNDS AND COMPOSITIONS AND USES THEREOF | PGI DRUG DISCOVERY LLC | 2018-02-01 | — | — | US | disclosed |
| WO-2018023070-A1 | COMPOUNDS AND COMPOSITIONS AND USES THEREOF | SUNOVION PHARMACEUTICALS, INC. (US) | 2018-02-01 | — | — | WO | disclosed |
| WO-2018023070-A1 | COMPOUNDS AND COMPOSITIONS AND USES THEREOF | SUNOVION PHARMACEUTICALS, INC. (US) | 2018-02-01 | — | — | WO | disclosed |
| WO-2003095441-A1 | INHIBITORS OF HEPATITIS C VIRUS RNA-DEPENDENT RNA POLYMERASE, AND COMPOSITIONS AND TREATMENTS USING THE SAME | PFIZER INC. (US) | 2003-11-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11077090-B2 | Compounds and compositions and uses thereof | ACHE, CHAT, MAOB | ALDH1A1 173/4885GABRA1 424/4885GABRB2 293/4885 |
| US-20180028492-A1 | COMPOUNDS AND COMPOSITIONS AND USES THEREOF | ACHE, CHAT, MAOB | ALDH1A1 173/4885GABRA1 424/4885GABRB2 293/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.